A second clinical trial testing fenebrutinib for MS has met its main goal, once again beating approved Aubagio in reducing ...

An estimated 2.8 million people worldwide are living with multiple sclerosis (MS), according to the National MS Society. March marks MS Awareness Month, a time dedicated to educating the public about ...

Continued treatment with Briumvi provided sustained clinical benefits to patients with relapsing MS, particularly when started earlier.

As recently as the ‘90s, when patients arrived with all the typical symptoms — memory loss, double vision, fatigue — neurologists often avoided confirming what they most suspected: that the patient ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...

Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

A novel program provided evidence that addressing long-known disparities in high-efficacy multiple sclerosis (MS) treatment for minority populations is a solvable problem. The program, presented by ...

Everclear frontman Art Alexakis opens up about living with living with multiple sclerosis for more than a decade, the early signs he missed, and why he considers his diagnosis a "blessing.' ...

A generation ago, most people with multiple sclerosis could expect to rely on walkers and wheelchairs or be limited to their bed within 15 years of diagnosis. Today, UC San Francisco’s discoveries are ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. March is Multiple Sclerosis Awareness Month, a time to ...